HOME › DRUGS › DEFERASIROX
ACTIVE SUBSTANCE / INN

DEFERASIROX

Brand name(s): JADENU SPRINKLE, Deferasirox Accord, Deferasirox Mylan, JADENU, Exjade, EXJADE, DEFERASIROX
FDA LISTED
EMA LISTED
PRESCRIPTION
DISCONTINUED
AUTHORISED
NDA206910
NDA021882
ACTIVE SUBSTANCE
Deferasirox
REGULATORS
FDA · EMA
SPONSORS / MAH
CIPLA, NOVARTIS PHARMS CORP, NOVARTIS
TOTAL APPLICATIONS
8
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
DEFERASIROXANDA203560ACTAVIS ELIZABETHPrescription
DEFERASIROXANDA211852CIPLADiscontinued
JADENUNDA206910NOVARTIS PHARMS CORPPrescription
EXJADENDA021882NOVARTISPrescription
JADENU SPRINKLENDA207968NOVARTISPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
ExjadeNovartis Europharm LimitedAuthorised28/08/2006beta-Thalassemia;Iron Overload
Deferasirox AccordAccord Healthcare S.L.U.Authorised09/01/2020Iron Overload;beta-Thalassemia
Deferasirox MylanMylan Pharmaceuticals LimitedAuthorised26/09/2019Iron Overload;beta-Thalassemia

FULL INTELLIGENCE ON DEFERASIROX

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →